Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience Corporation (NASDAQ: TWST) has priced an upsized public offering of 4,545,454 shares at $55.00 each, aiming for gross proceeds of approximately $250 million. The offering is set to close around February 15, 2022, subject to customary conditions. Proceeds will fund R&D investments, including pharmaceutical biologics drug discovery and DNA data storage, as well as scaling operations and supporting global expansion. The underwriters are granted a 30-day option to buy an additional 681,818 shares.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 8:00 a.m. Eastern Time. The event will be webcast live, accessible through the Investor Calendar on the company’s website, with a replay available for 30 days. Twist Bioscience is a leader in synthetic biology, using a unique silicon-based DNA synthesis platform to produce synthetic DNA products across various industries, including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) announced a public offering of up to $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering's completion and terms are subject to market conditions. Proceeds will fund R&D for pharmaceutical biologics and DNA data storage, expand the commercial organization, and support NGS operations. The offering is registered with the SEC under Form S-3. J.P. Morgan, Goldman Sachs, Cowen, and William Blair are acting as joint managers.
Twist Bioscience (NASDAQ: TWST) and C2i Genomics have partnered to develop whole-genome cancer reference materials. This collaboration aims to enhance cancer diagnostics by creating standardized reference samples for labs, enabling better validation of whole-genome assays. C2i will utilize AI to identify cancer-associated genomic variants, which Twist will synthesize to form comprehensive reference kits. The initiative seeks to address the urgent need for validated materials in cancer detection and aims to improve accessibility and precision in oncology care worldwide.
Twist Bioscience (NASDAQ: TWST) and Eleven Therapeutics have developed a replicon tool to enhance the study of viral genome replication and advance antiviral drug screening, as well as vaccine and therapeutic development. The SARS-CoV-2 replicon retains 97% of the viral genome but eliminates its infectivity. This system can facilitate rapid therapeutic development and testing of drug efficacy against various variants. Twist has also established a biosafety committee to oversee related research, underscoring its commitment to safety in biotech innovation.
Twist Bioscience (NASDAQ: TWST) reported a strong first quarter of fiscal 2022, achieving record revenues of $42 million, a 49% increase from $28.2 million in fiscal 2021. Orders rose 48% to $49.6 million. R&D expenses increased to $22.6 million, while net loss widened to $45.6 million or $0.91 per share. The company's cash position stood at $408.7 million. Key developments included collaborations in biopharma and the introduction of new products for liquid biopsy and DNA data storage solutions.
Twist Bioscience (TWST) has entered a licensing agreement with Abcam (ABCM) for the use of its proprietary VHH phage library, enhancing Abcam's recombinant antibody capabilities. Abcam plans to develop and commercialize antibodies for diagnostics and research, while Twist retains rights for therapeutic applications. This partnership aims to improve industry standards by delivering high-quality reagents and expanding access to challenging antibody targets, with potential commercial benefits for both companies.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with Artisan Development Labs Inc. to discover novel antibodies for five undisclosed targets. Twist will utilize its proprietary Library of Libraries, while Artisan will employ its Immune Cell Engineering Foundry to develop custom cell therapeutics. The partnership includes upfront fees, success-based milestones, and royalties on product sales. This collaboration aims to enhance antibody discovery and advance next-generation cell therapies, combining Twist's DNA synthesis platform with Artisan's engineering capabilities.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its financial results for the first quarter of fiscal 2022, ending December 31, 2021, before the market opens on
Twist Bioscience Corporation has announced a breakthrough in DNA synthesis with its new enzymatic synthesis process, offering low-cost, scarless, and scalable technology. The innovation reduces the nucleotide triphosphate (NTP) requirement, significantly cutting costs and enhancing sustainability. Additionally, Twist is partnering with PacBio and Singular Genomics to streamline next-generation sequencing workflows. CEO Emily M. Leproust will present these advancements at the 40th Annual J.P. Morgan Healthcare Conference, aimed at expanding applications in various markets.
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
